On October 22, 2026 EORTC reported it will showcase a strong portfolio of oral and poster presentations at the ESMO (Free ESMO Whitepaper) Congress 2026, taking place in Madrid, Spain, from 23-27 October 2026. Oral presentations will feature results from clinical and translational research studies, while a broad poster programme will highlight ongoing and planned trials, methodological research, patient involvement initiatives, and quality of life research, reflecting the breadth of EORTC’s multidisciplinary cancer research programme.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EORTC ABSTRACTS
ORAL PRESENTATIONS
INFORMED CONSENT MATERIALS THROUGH THE EYES OF PATIENTS: A QUALITATIVE ANALYSIS OF EORTC PATIENT REVIEWS
Iryna Shakhnenko, Belgium Saturday, 24 October 2026, 15:47 – 15:52
Type: Rapid Oral Session
Location: Seville Auditorium – NCC
Abstract number: 3324RO
COMPARABLE SWALLOWING FUNCTION AT 12 MONTHS BUT DIVERGENT TOXICITY PROFILES WITH TOS VERSUS DO-IMRT IN EARLY-STAGE OROPHARYNGEAL, SUPRAGLOTTIC AND HYPOPHARYNGEAL CARCINOMA: PRIMARY RESULTS OF THE PHASE III EORTC 1420 BEST-OF TRIAL
Christian Simon, Switzerland Sunday, 25 October 2026, 09:28 – 09:38
Type: Proffered Paper Session
Location: Madrid Auditorium – Hall 4
Abstract number: 1535O
FINAL ANALYSIS OF ADJUVANT PEMBROLIZUMAB (PEMBRO) IN RESECTED EARLY-STAGE NON-SMALL-CELL LUNG CANCER (NSCLC): PHASE 3 PEARLS/KEYNOTE-091 STUDY
Mary O’Brien, United Kingdom Monday, 26 October 2026, 15:43 – 15:53
Type: Proffered Paper Session
Location: Alicante Auditorium – Hall 6
Abstract number: 2511O
POSTERS
IMPACT OF ENZALUTAMIDE-RELATED DRUG–DRUG INTERACTIONS ON ADVERSE EVENTS IN THE EORTC 1333GUCG PEACE-3 TRIAL
Mehdi Bsilat, Belgium Friday, 23 October 2026, 15:15 – 16:00
Type: Poster Session
Location: Lorem ipsum
Abstract number: 2245P
ADJUVANT TEBENTAFUSP (IMCGP100) VERSUS OBSERVATION IN HLA-A*02:01 POSITIVE PATIENTS FOLLOWING DEFINITIVE TREATMENT OF HIGH-RISK UVEAL MELANOMA: AN EORTC RANDOMIZED PHASE III STUDY
Paul Nathan, United Kingdom Saturday, 24 October 2026, 12:00 – 12:45
Type: Trial in Progress Poster
Location: Lorem ipsum
Abstract number: 2139TiP
≥4 POSITIVE NODES IDENTIFY A POPULATION ENRICHED FOR ctDNA-GUIDED ADJUVANT TREATMENT ESCALATION IN ER+/HER2− EARLY BREAST CANCER
Teck Long King, Belgium Saturday, 24 October 2026, 12:00 – 12:45
Type: Poster Session
Location: Lorem ipsum
Abstract number: 583P
ANALYSIS AND REPORTING OF PFS IN CONTEMPORARY PHASE 2-3 TRIALS IN SOLID ONCOLOGY: A SYSTEMATIC REVIEW
Annemiek Van Ommen-Nijhof, Netherlands Sunday, 25 October 2026, 12:00 – 12:45
Type: Poster Session
Location: Lorem ipsum
Abstract number: 3332P
CURRENT PRACTICE CONSIDERATIONS FOR BRAIN METASTASES IN GASTROESOPHAGEAL CANCER PATIENTS: AN INTERNATIONAL EORTC SURVEY
Hannah C. Puhr, Austria Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 749eP
COVERAGE OF TREATMENT-RELATED TOXICITIES BY EORTC QLQ-C30 AND QLQ-H&N43 IN HEAD AND NECK CANCER
Myrto Moutafi, Greece Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 1622eP
DIAGNOSIS, TREATMENT AND FOLLOW-UP PRACTICES FOR LOCALLY ADVANCED NASOPHARYNGEAL CANCER (NPC) IN NON-ENDEMIC REGIONS: AN EORTC LED SURVEY
Alvina Vadassery, Belgium Lorem ipsum
Type: E-Poster
Location: Lorem ipsum
Abstract number: 1623eP
(Press release, EORTC, OCT 22, 2026, View Source [SID1234673669])